이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Hansoh Pharmaceutical Group 관리
관리 기준 확인 2/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Huijuan Zhong
최고 경영자
CN¥14.8m
총 보상
| CEO 급여 비율 | 49.6% |
| CEO 임기 | 8.8yrs |
| CEO 소유권 | n/a |
| 경영진 평균 재임 기간 | 8.5yrs |
| 이사회 평균 재임 기간 | 6.9yrs |
최근 관리 업데이트
Recent updates
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Aug 28
Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now
Aug 07If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity
Jul 16Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Jun 24Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 06Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
May 23Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 01Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly
Dec 08Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate
Oct 12Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's
Sep 14These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Sep 09Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 10These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Jun 11Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jan 23Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Dec 01Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price
Oct 19Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Aug 28An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
Jun 09Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing
May 19Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
Apr 22An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued
Feb 06Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 43% Above Its Share Price
Nov 07Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Oct 11CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥5b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥15m | CN¥7m | CN¥3b |
| Sep 30 2023 | n/a | n/a | CN¥3b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥11m | CN¥5m | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥3b |
| Dec 31 2021 | CN¥16m | CN¥8m | CN¥3b |
보상 대 시장: Huijuan 의 총 보상 ($USD 2.04M )은 Hong Kong 시장( $USD 891.29K ).
보상과 수익: Huijuan 의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Huijuan Zhong (63 yo)
8.8yrs
테뉴어
CN¥14,807,000
보상
Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairlady | 8.8yrs | CN¥14.81m | 데이터 없음 | |
| Executive Director | 8.5yrs | CN¥9.39m | 0.023% CN¥ 30.1m | |
| Executive Director | 8.8yrs | CN¥16.63m | 0.021% CN¥ 27.0m | |
| VP & CFO | no data | 데이터 없음 | 데이터 없음 | |
| Chief of Science Officer | 2.4yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President | 15.5yrs | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | no data | 데이터 없음 | 데이터 없음 | |
| Joint Company Secretary & Senior VP | 6.1yrs | 데이터 없음 | 데이터 없음 | |
| Joint Company Secretary | less than a year | 데이터 없음 | 데이터 없음 |
8.5yrs
평균 재임 기간
54.5yo
평균 연령
경험이 풍부한 관리: 3692 의 관리팀은 노련하고 경험 (평균 재직 기간 8.3 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairlady | 8.8yrs | CN¥14.81m | 데이터 없음 | |
| Executive Director | 8.5yrs | CN¥9.39m | 0.023% CN¥ 30.1m | |
| Executive Director | 8.8yrs | CN¥16.63m | 0.021% CN¥ 27.0m | |
| Independent Non-Executive Director | 5.3yrs | CN¥360.00k | 데이터 없음 | |
| Independent Non-Executive Director | 5.3yrs | CN¥360.00k | 데이터 없음 | |
| Independent Non-Executive Director | 5.3yrs | CN¥360.00k | 데이터 없음 |
6.9yrs
평균 재임 기간
65yo
평균 연령
경험이 풍부한 이사회: 3692 의 이사회는 경험(평균 재직 기간 6.7 년)으로 간주됩니다.